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Abstract
Background
Antimicrobials are the most commonly prescribed drugs. Many studies have evaluated anti-
biotic prescriptions in the paediatric outpatient but few studies describing the real antibiotic
consumption in Italian children’s hospitals have been published. Point-prevalence survey
(PPS) has been shown to be a simple, feasible and reliable standardized method for antimi-
crobials surveillance in children and neonates admitted to the hospital. In this paper, we pre-
sented data from a PPS on antimicrobial prescriptions carried out in 7 large Italian
paediatric institutions.
Methods
A 1-day PPS on antibiotic use in hospitalized neonates and children was performed in Italy
between October and December 2012 as part of the Antibiotic Resistance and Prescribing
in European Children project (ARPEC). Seven institutions in seven Italian cities were
involved. The survey included all admitted patients less than 18 years of age present in the
ward at 8:00 am on the day of the survey, who had at least one on-going antibiotic prescrip-
tion. For all patients data about age, weight, underlying disease, antimicrobial agent, dose
and indication for treatment were collected.
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Results
The PPS was performed in 61 wards within 7 Italian institutions. A total of 899 patients were
eligible and 349 (38.9%) had an on-going prescription for one or more antibiotics, with vari-
able rates among the hospitals (25.7% - 53.8%). We describe antibiotic prescriptions sepa-
rately in neonates (<30 days old) and children (> = 30 days to <18 years old). In the
neonatal cohort, 62.8% received antibiotics for prophylaxis and only 37.2% on those on
antibiotics were treated for infection. Penicillins and aminoglycosides were the most pre-
scribed antibiotic classes. In the paediatric cohort, 64.4% of patients were receiving antibiot-
ics for treatment of infections and 35.5% for prophylaxis. Third generation cephalosporins
and penicillin plus inhibitors were the top two antibiotic classes. The main reason for pre-
scribing antibiotic therapy in children was lower respiratory tract infections (LRTI), followed
by febrile neutropenia/fever in oncologic patients, while, in neonates, sepsis was the most
common indication for treatment. Focusing on prescriptions for LRTI, 43.3% of patients
were treated with 3rd generation cephalosporins, followed by macrolides (26.9%), quino-
lones (16.4%) and carbapenems (14.9%) and 50.1% of LRTI cases were receiving more
than one antibiotic. For neutropenic fever/fever in oncologic patients, the preferred antibiot-
ics were penicillins with inhibitors (47.8%), followed by carbapenems (34.8%), aminoglyco-
sides (26.1%) and glycopeptides (26.1%). Overall, the 60.9% of patients were treated with a
combination therapy.
Conclusions
Our study provides insight on the Italian situation in terms of antibiotic prescriptions in hospi-
talized neonates and children. An over-use of third generation cephalosporins both for pro-
phylaxis and treatment was the most worrisome finding. A misuse and abuse of
carbapenems and quinolones was also noted. Antibiotic stewardship programs should
immediately identify feasible targets to monitor and modify the prescription patterns in chil-
dren’s hospital, also considering the continuous and alarming emergence of MDR bacteria.
Background
Antimicrobials are the most commonly prescribed drugs in the community and hospital set-
ting, especially among paediatric patients [1]. However, antibiotics are often unnecessarily
used both in the community, where too many children receive broad-spectrum antibiotics for
viral infections, and in the hospital, where long courses of broad-spectrum antibiotics are fre-
quently prescribed [2]. Recent studies have found that up to 50% of antimicrobial prescriptions
are inappropriate [3,4].
The emergence of multi-drug resistant (MDR) pathogens and their rapid global spread,
strictly associated with an inappropriate use of antimicrobials, are important global public health
threats with a substantial impact on patient outcomes such as hospital length of stay and mortal-
ity, as well as on healthcare costs [5–8]. The European Antimicrobial Resistance Surveillance Net-
work (EARS-Net) system has reported a dangerous rise in MDR bacteria in the last years
showing that some countries such as Italy are strongly contributing to this worrying increase [9].
Many studies have evaluated antibiotic prescriptions in the paediatric outpatient population
highlighting the problem that Italian prescribing habits that differ from those of other
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European countries. An Italian child is more likely to be exposed to antibiotics than children are
in North Europe [10] and, in particular, the prevalence of antibiotic prescriptions in childhood
have been reported to be 4 times higher than in the UK and 6 times higher than in the Nether-
lands [11,12]. Moreover, Italy reported the highest prescription rate (1.3 per infants per year) in a
study comparing antibiotic use in the first year of life in five European countries [13]. In fact, data
from the Gagliotti et al study in 2006 show that the 55% of Italian infants in the community have
already received at least one course of antibiotics at 1 year of age and 84% at 2 years of age [14].
Although a positive correlation between outpatient and inpatient antibiotic use has been
noted [15], few studies describing the real antibiotic consumption in Italian children’s hospitals
have been published. A single centre study was carried out in Rome in 2008 [16] confirming
the abuse of antibiotics observed in the outpatient population. A more recent paper evaluating
the trend of antibiotic use in all the paediatric wards of Emilia-Romagna Region over an
8-year-period [17] indicated a slight increase of antibiotic consumption over time, an inade-
quate tendency to prefer penicillin plus inhibitors to plain penicillins, an over-use of third gen-
eration cephalosporins and a worrisome increase in linezolid prescriptions.
In this paper, we present the results of a point-prevalence survey (PPS) on antibiotic pre-
scriptions carried out in seven large Italian paediatric institutions in 2012. The aims of our
study were: i) to describe prevalence rates of antibiotic prescriptions for prophylaxis and treat-
ment of infections for neonatal (<30 days) and paediatric (age30 days) patients in seven Ital-
ian centers; ii) to evaluate antibiotic prescriptions, indications, number and type of antibiotic
agents and administration route in the same age sub-groups both for prophylaxis and treat-
ment of infections; iii) to describe over-all consumption and off-label use of particular classes
of antibiotics, such as carbapenems and quinolones, in our cohort; and iiii) to identify targets
for improving the quality of antimicrobial prescribing in these centers.
Methods
This research has been conducted according to the principles expressed in the Declaration of
Helsinki. Ethical approval has been obtained for the coordinating centre. No consent was given,
because data were collected by reviewing medical charts and were analyzed anonymously. Every
patient record was given a unique non-identifiable survey number, which was automatically gen-
erated by a computer program specifically designed for anonymous data entry.
A 1-day PPS on antibiotic use in hospitalized children was performed in Italy between Octo-
ber and December 2012 as part of the Antibiotic Resistance and Prescribing in European Chil-
dren project (ARPEC). Seven paediatric or mixed adult-paediatric hospitals in seven Italian cities
were involved (Genoa, Milan, Padua, Florence, Viareggio, Rome and Naples). The survey
included all admitted patients less than 18 years of age present in the ward at 8:00 am on the day
of the survey who had at least one on-going antibiotic prescription. The wards of admission
were: medical (general neonatal and maternal wards, and general paediatric wards), special medi-
cal (cardiology, nephrology, onco-hematology, neuromuscolary, neurology, bronchopneumol-
ogy, infectious diseases unit), neonatal and paediatric intensive care (NICUs and PICUs),
surgical (neonatal surgery, paediatric surgery, orthopedics, neurosurgery). For feasibility reasons,
one hospital provided data from randomly selected wards, maintaining the patient distribution
among medical, special medical, surgical and intensive care units, in agreement with the coordi-
nating centre. Full details of the ARPECmethodology are described elsewhere [18].
Results
The PPS was performed in 61 wards within seven Italian institutions. Characteristics of the
centres involved are shown in Table 1. A total of 899 patients was present in the hospitals at
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8:00 am on the day of the survey and 349 (38.9%) of these had an on-going prescription for
one or more antibiotics. However, this rate was variable among the hospitals ranging from
25.7% to 53.8% (Table 1). Combination therapies were variably used among the institutions
(21.7–60.3%) with a ratio between number of prescribed antibiotics and treated patients rang-
ing from 1.25 to 1.76 (Table 1).
A wide variability also existed in the proportions of patients treated with at least one antibi-
otic stratified by ward type. In particular, special medical wards and intensive care units
accounted for higher proportions of patients receiving antibiotics compared to surgical and
medical wards (“Fig 1”).
Characteristics of all patients enrolled are summarized in Table 2. Median patient age was
24 months and 12.3% were less than 30 days old. Overall, 24.6% of patients were affected by a
medical/surgical underlying condition and the most frequent was an oncologic/hematologic
disease. Noteworthy is that the rate of oncologic/hematologic patients admitted to the hospital
at the time of the survey was 5% (45/899), but this rate increased to 22.3% (78/349) looking at
the group of patients receiving antibiotics. These data reflect the fact that oncologic and hema-
tologic patients were responsible for a large proportion of antibiotic consumption in our
survey.
We analyzed antibiotic prescriptions separately in neonates and children (Table 3).
Neonates
At the time of the survey, 248 neonates were admitted in participating hospitals and 43 were
receiving antibiotics (17.3%). As shown in Table 3, neonates treated with antibiotics were
mostly admitted in the NICUs (83.7%, 36/43). Moreover, 62.8% (27/43) of newborns were
Table 1. Characteristics of the 7 Italian institutions involved in the ARPEC project.
City Hospital
Characteristics
Treated
patients
Total
patients
Rates of
treatment
Beds Bed
occupancy
N° of
prescribed
antibiotics
N° of
prescribed
antibiotics/
treated
patients
Combination
therapies
Combination
therapies/
treated
patients
Rome Teaching
hospital, tertiary
hospital
63 117 53.8% 136 86.0% 111 1.76 38 60.3%
Padua Teaching
hospital, tertiary
hospital
70 185 37.8% 213 86.9% 124 1.77 36 51.4%
Florence Teaching
hospital, tertiary
hospital
59 144 41.0% 169 85.2% 98 1.66 26 44.1%
Milan Teaching
hospital,
specialized
hospital
38 100 38.0% 128 78.1% 55 1.45 14 36.8%
Genoa Teaching
hospital, tertiary
hospital
83 217 38.2% 314 69.1% 104 1.25 18 21.7%
Naples Teaching
hospital,
specialized
hospital
28 109 25.7% 122 89.3% 42 1.50 11 39.3%
Viareggio Secondary
hospital
8 27 29.6% 45 60.0% 9 1.13 1 12.5%
TOT - 349 899 38.8% 1127 79.8% 543 1.56 144 41.3%
doi:10.1371/journal.pone.0154662.t001
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receiving antibiotics for prophylaxis and only 37.2% (16/43) were being treated for infection.
The top two active antibiotic prescriptions were penicillins (69.8%, 30/43) and aminoglycosides
(58.1%, 25/43). Details about indications to receive antibiotics are summarized in Table 3. All
antibiotic classes prescribed are listed in “Fig 2”.
Fig 1. Proportion of paediatric patients treated with at least one antibiotic by ward type.
doi:10.1371/journal.pone.0154662.g001
Table 2. Characteristics of the 349 Italian patients enrolled in the 24-hour ARPEC PPS.
Median age 2 years (IQR 0.5–9)
Neonates 12.3% (n = 43/349)
Children 87.7% (n = 306/349)
Male/Female 201/148
Underlying conditions: 86/349
• Oncologic/hematologic disease 22.3%
• Surgical problem 20.8%
• Chronic lung disease 7.6%
• Respiratory distress syndrome 7.6%
• Chronic neurological condition 7%
• Congenital heart disease 6.7%
• Genetic and metabolic disease 6.4%
• Chronic renal disease 5.2%
• Prematurity and IUGR 4.9%
• Gastrointestinal disease 4.3%
• Other/unknown 4%
• Congenital immunodeficiency 2.4%
• Rheumatological disease 0.6%
IQR = interquartile range
doi:10.1371/journal.pone.0154662.t002
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Antibiotic prophylaxis in neonates
The main indication to prescribe antibiotic prophylaxis was medical risk factors (e.g. prematurity,
maternal fever during labor, prolonged rupture of the membranes), accounting for 55.8% of all
indications for antibiotic therapy in the neonatal subset. The other neonatal patients were receiv-
ing prophylaxis for surgical reasons. Monotherapy was prescribed in 10 of the 27 patients on pro-
phylaxis (37%), and penicillin was the most prescribed antibiotic (7/10). Combination therapies
in the other 17/27 patients (63%) were variable: penicillins were combined with aminoglycosides
in 7/17 cases, while glycopeptides were used with third generation cephalosporins in 3 cases and
with aminoglycosides in 3 cases. The last 4 patients received 3 drug combination therapy, includ-
ing glycopeptides plus aminoglycosides combined with metronidazole (2/4) or penicillin (2/4).
Antibiotic treatment in neonates
Among all the indications for antibiotic treatment of infection in neonates, the most common
was sepsis (30.2%, 13/43). Monotherapy was used just in two cases (one case treated with
Table 3. Demographic characteristics and antibiotic prescription patterns of the neonates and children enrolled in the study.
NEONATES CHILDREN
Department of admission:
NICU 36
(83.7%)
Special medical ward 131
(42.8%)
General neonatal and paediatric
department
4 (9.3%) General paediatric ward 72 (23.5%)
Special medical wards 3 (7%) Surgery 59 (19.3%)
PICU 26 (8.5%)
NICU 18 (5.9%)
Indications to antibiotic therapy:
Prophylaxis for medical problems 24
(55.8%)
LRTI 68 (22.1%)
Sepsis 13
(30.2%)
Prophylaxis for surgical disease 57 (18.6%)
Prophylaxis for surgical problems 3 (7%) Prophylaxis for medical problem 52 (16.9%)
Skin and soft tissue infections 1 (2.3%) Febrile neutropenia/fever in oncologic
patient
23 (7.5%)
Pyrexia of unknown origin 1 (2.3%) Treatment for surgical disease 16 (5.2%)
LRTI 1 (2.3%) Other/unknown 15 (4.9%)
Sepsis 13 (4.2%)
UTI (upper and lower) 12 (3.9%)
Upper respiratory tract infection 8 (2.6%)
Catheter related bloodstream infection 8 (2.6%)
Skin and soft tissue infection 7 (2.3%)
Gastrointestinal tract infection 7 (2.3%)
Pyrexia of unknown origin 6 (1.9%)
CNS infection 6 (1.9%)
Joint/bone infection 4 (1.3%)
Tubercolosis 2 (1%)
Lymphadenitis 1 (0.3%)
Acute osteomyelitis 1 (0.3%)
Associations with antifungal
agents
8 (18.6%) 48 (15.6%)
Associations with antiviral agents 0 21 (6.8%)
doi:10.1371/journal.pone.0154662.t003
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ampicillin and the other treated with meropenem). Penicillins plus aminoglycosides was by far
the preferred combination therapy (8/11), while in the other patients (3/11) glycopeptides were
used widely in combination with other classes of antibiotics.
Children
The paediatric group was composed of 651 patients, 47% (306/651) of whom had an active
antibiotic prescription at the time of the PPS. In the group of patients with active antibiotic pre-
scriptions, 64.4% (197/306) were being treated for infections and 35.5% (109/306) for prophy-
laxis (Table 3). Third generation cephalosporins and penicillin plus enzyme inhibitors were the
most commonly used antibiotic classes. More details about indications to therapy are reported
in Table 3. All antibiotic classes prescribed are listed in “Fig 2”.
Antibiotic prophylaxis in children
Approximately half of the children on antibiotics for prophylaxis received antibiotics for surgi-
cal reasons (52.3%, 57/109), the others for medical problems (47.7%, 52/109). The most pre-
scribed antibiotics were third generation cephalosporins for surgery (35.9%, 20/57), used as
monotherapy in 14/20 cases and combined most often with metronidazole in the other cases
(3/20). Cotrimoxazole was the most commonly prescribed agent for the medical problems
(67.3%, 35/52), mainly used as monotherapy (30/35).
Antibiotic treatment in children
The main reason for prescribing antibiotics for infection among children was lower respiratory
tract infections (LRTI) (34%, 67/197), followed by febrile neutropenia/fever in oncologic
patients (11.7%, 23/197). Focusing on prescriptions for LRTI, 43.3% (29/67) of patients were
treated with third generation cephalosporins, followed by macrolides (26.9%, 18/67), quino-
lones (16.4%, 11/67) and carbapenems (14.9%, 10/67). Cephalosporins were used as monother-
apy in 13/29 cases and combined in the other 16 cases, mostly with macrolides (6/16). For
73.1% (49/67) of children with LRTI, the route of antibiotic administration was parenteral.
For oncology patients affected by neutropenic fever/fever, the preferred antibiotics were
penicillins with enzyme inhibitors (47.8%, 11/23), followed by carbapenems (34.8%, 8/23),
aminoglycosides (26.1%, 6/23) and glycopeptides (26.1%, 6/23). Penicillins with enzyme inhib-
itors were used in monotherapy in 5/11 cases and combined mostly with aminoglycosides in
the other 6 cases. Carbapenem monotherapy was prescribed in 4/8 cases, while combination
therapy with anti-Gram positive agents (glycopeptides or oxazolidinones) was preferred in the
other cases. The route of antibiotic administration was parenteral in the 95.7% of cases (22/23).
Use of Carbapenems
Among the 899 patients admitted to the hospital at the time of the survey, 32 (3.6%) were
being treated with carbapenems. Focusing on the group of 349 patients with active antibiotic
prescriptions at the time of the PPS, 8.9% (32/349) were receiving carbapenems (in particular
4.6% [2/43] in the neonatal group and 9.8% [30/306] in the paediatric group). Considering the
overall rates of therapy by department, those with the highest rates of carbapenem prescription
were the special medical wards (14.2%, 19/134) and the intensive care units (11.2%, 9/80), com-
pared to 2.6% (2/76) in medical wards and 1.7% (1/59) in surgical wards. Indications for pre-
scription of carbapenems were community-acquired infections in 53.1% of cases, hospital-
acquired infections in 37.5% and prophylaxis in 9.3%. Febrile neutropenia was the most com-
mon reason for carbapenem prescription (34.8%, 8/23). Therapy was empirically prescribed in
Antibiotic Prescriptions in Italian Children
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62.5% (20/32) of patients. Carbapenems were mostly prescribed in combination with one or
more other antibiotics (65.6%, 21/32), most commonly with glycopeptides (10/21), followed by
quinolones (4/21), cotrimoxazole (4/21) and aminoglycosides (3/21). Meropenem was the
most prescribed carbapenem, with great heterogeneity in doses and number of administrations
Fig 2. Antibiotic prescriptions among the neonates and children.
doi:10.1371/journal.pone.0154662.g002
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recorded. Daily doses of meropenem ranged from 19 mg/kg/day to 129 mg/kg/day, while the
mean dose was 70 mg/kg/day. Off-label prescription of carbapenems (i.e. below 3 months of
age) was recorded in 18.7% (6/32) of patients and the indications were LRTI, sepsis and surgi-
cal prophylaxis.
Use of Quinolones
In the entire cohort of patients admitted to the hospital, 3% (27/899) were prescribed quino-
lones. Among the patients with active antibiotic prescriptions, this rate was 7.7% (27/349).
None of them were neonates, but 37% (10/27) were below 2 years of age. Considering the over-
all rates of prescriptions into the departments, the special medical wards (10.4%, 14/134) and
intensive care units (7.5%, 6/80) reported the highest rates of quinolone prescription, com-
pared to 6.6% (5/76) in medical wards and 3.4% (2/59) in surgical wards. Indications for pre-
scription of quinolones were community-acquired infections in 44.4% of cases, hospital-
acquired infections in 40.7%and prophylaxis in 14.8%. Considering the rates of antibiotic pre-
scription by indication, the most common indication was LRTI (17.6%, 12/67). Among the
group affected by LRTI, 41.6% (5/12) had an underlying chronic lung disease including cystic
fibrosis and 25% (3/12) congenital immunodeficiency. In general, quinolone therapy was
empirically prescribed in 63% of patients. Quinolones were prescribed as monotherapy just in
29.6% (8/27) of patients. In the other cases, they were widely combined with other antibiotics
(70.4%, 19/27), especially with third generation cephalosporins (5/19). The mostly prescribed
quinolone was ciprofloxacin. Focusing on ciprofloxacin, the prescribed daily dose ranged from
6 mg/kg/day to 30 mg/kg/day, while the mean dose was 18 mg/kg/day.
Discussion
The 1-day ARPEC PPS provided very useful data on hospital antibiotic prescriptions for paedi-
atric and neonatal patients in Italy. According to data collected in seven large Italian institu-
tions, 38.9% of inpatients received at least one antibiotic prescription during hospitalization.
This rate is similar to the mean rate reported from the worldwide ARPEC PPS (36.7%) [18].
To better analyze antibiotic prescription patterns and their appropriateness, we assessed
antibiotic prescriptions for prophylaxis and treatment of infection separately.
Our results show that overall 39% of patients were prescribed antibiotics for prophylaxis
with the highest rate observed in the neonatal population (63% of neonatal prescriptions were
for this indication). The main indication for neonatal prophylaxis was the presence of perinatal
conditions (e.g. prematurity, maternal fever during labor, prolonged rupture of the mem-
branes). Prophylactic monotherapy was prescribed just in 37% of neonates and penicillin was
the preferred agent, while combination prophylactic therapies including penicillin plus amino-
glycosides or glycopeptides plus cephalosporins/aminoglycosides were widely used in neonatal
patients. This approach is not in-line with the international literature. Although neonates rep-
resent a high risk population due to their immature immune system and the invasive procedure
they are likely to undergo in NICU (e.g. indwelling catheters, invasive mechanical ventilation),
recent reviews reject the routine use of antibiotic prophylaxis due to lack of efficacy in many
conditions [19–22]. Moreover, in 2010 the Center for Disease Control and Prevention revised
their guidelines regarding the prevention of perinatal Group B streptococcal disease in healthy
neonates, restricting the need for prophylaxis only to well-defined subgroups of patients [23].
Prolonged courses of antibiotics have also been associated with increased risk of necrotizing
enterocolitis or death in low birth weight infants [24].
In the paediatric group, the rate of antibiotic prescriptions for prophylaxis was 35.5% of all
the prescriptions. Approximately, half of these patients were receiving antibiotics for surgical
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prophylaxis in accordance with previous European reports in which the proportion of children
receiving surgical prophylaxis ranged from 13 to 42% [25, 26]. Third generation cephalospo-
rins ranked first in prescription frequency in this scenario, used often in monotherapy but
combined with metronidazole in some cases, confirming their alarming overuse for this indica-
tion. This problem in fact was already raised by Ciofi et al in 2008 [16], but a recent paper pub-
lished by Buccellato et al in 2015 shows that a limitation on the prescriptions of these drugs has
not yet been reached [17]. However, it is worth noting that this finding was very variable
among the seven centers, since some hospitals preferred the first generation cephalosporins for
surgical prophylaxis, as suggested by international guidelines [27].
Cotrimoxazole was the most prescribed antibiotic for medical prophylaxis, used alone in
most cases. As explanation, most of the treated children were affected by onco-hematological
diseases and cotrimoxazole is the best treatment to prevent Pneumocystis jirovecii pneumonia
in immunocompromised patients [28].
Regarding the prescription patterns for treatment of infection, the 37.2% of our neonatal
cohort was prescribed at least one antibiotic for treating an infection, the main reason was sep-
sis and the most common antibiotic class was penicillins, combined with aminoglycosides in a
large number of patients, in line with international literature [29, 30]. It is hard to compare pre-
scription habits in our centres with other NICUs because of a wide variability of the rate of neo-
nates prescribed antibiotics across hospitals, as shown by a recent multicenter study involving
127 NICUs in the US [31]. The 40-fold variations in prescription frequencies noted in this
study did not appear to be related to higher infection burden, necrotizing enterocolitis inci-
dence, surgical volume or mortality rate [31]. They have instead been attributed to frequent
inappropriate courses of antibiotics in inpatient neonates, more commonly owing to an unnec-
essary antibiotic continuation than starting of a non-required therapy [32].
Focusing instead on the paediatric group, we noticed an excessive use of third generation
cephalosporins for treatment of infection similar to that seen for surgical prophylactic use, as
underlined before. In children with LRTIs, ceftriaxone was the most prescribed antibiotic, used
as monotherapy or often combined with macrolides, with a wide total daily dose variability
ranging from 12.1 mg/kg/day to 153.8 mg/kg/day. The frequent choice of ceftriaxone as first
line therapy for treatment of uncomplicated LRTIs and, in some cases, the high dosage pre-
scribed, are reasons of concern because they are not supported by current guidelines [33]. In
fact, other European countries, as the UK and France, seem to have different prescribing pat-
terns for LRTI, preferring amoxicillin/clavulanic acid as first line therapy [34].
An abuse of parenteral cephalosporins in Italian hospitalized children was already
denounced in a study conducted by Esposito in 2001 [35] and is a well-known problem also in
the adult population [36].
Noteworthy was also the widespread use of carbapenems and quinolones. Indeed, in our study
population, among the 349 patients receiving antibiotics, 8.9% were being treated with carbape-
nems, whereas proportion of carbapenems for therapeutic use reported in the literature in Euro-
pean paediatric units is 4,2% [37]. Though carbapenems were prescribed in most cases for fever
in cancer patients, which often requires aggressive antibiotic treatment considering the patients’
immunological status and predisposition to severe infections, we are concerned about the increas-
ingly popular usage of these agents for community acquired-infections, empiric treatment and
combination therapy. This is a very alarming finding, considering the doubling of carbapenem
resistance rates in invasive isolates of Klebsiella pneumoniae reported by the European Antimicro-
bial Resistance Surveillance Network (EARS-Net)’s report from 2010 to 2013 [9] for Italy. We
also found 18.7% off-label use in patients below 3 months of life, but this could be explained by
the involvement of many of our centers in the European NEOMERO study, which aimed to eval-
uate pharmacokinetics, safety and efficacy of meropenem in neonatal sepsis and meningitis [38].
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Similar problems were noticed also for quinolone prescription. Quinolones were widely
used in our cohort, even if the license for the use of this antibiotic class below 18 years of age is
restricted to few rare indications such as cystic fibrosis with pulmonary exacerbations, compli-
cated urinary tract infections, post exposure prophylaxis against inhalational anthrax and
severe infections with allergies to other antibiotics [39,40]. Among our patients, the main indi-
cation for treatment with quinolones was LRTI. In this group of patients, quinolones were
often prescribed empirically and combined with other drugs, though current guidelines do not
suggest quinolones as a first-line treatment considering that infections caused by pneumococci
or atypical bacteria can still be successfully treated with high doses of β-lactams [41]. Further-
more, the Scottish Antimicrobial Prescribing Group (SAGP) in 2008 and the National Institute
for Health and Care Excellence (NICE) in 2015 [42] recommended to avoid the use of quino-
lones as first line agents for empirical treatment of most commonly infections in primary care,
because the overuse of these broad-spectrum antibiotics is associated with a significantly
increased risk of Clostridium difficile infection [43,44]. The wide use of quinolones in our
cohort could be explained by the finding that most of our patients receiving this treatment had
underlying chronic pulmonary diseases, such as cystic fibrosis or secondary to immunodefi-
ciencies, but the lack of data about their microbiological status did not allow us to evaluate the
appropriateness of these prescriptions.
Our study highlights many feasible targets that need a prompt intervention with appropriate
antimicrobial stewardship programs. International guidelines for stewardship identify a wide
set of interventions including: disease-specific clinical pathways, audit with feedback and for-
mulary restriction with preauthorization of select agents. The best type of interventions must
be tailored according to local practices, resistance trends, and available resources [4]. While the
most effective antimicrobial stewardship programs are built on proactive interventions, in set-
tings where a robust antimicrobial stewardship team is hard to establish, clinical pathways tool
represent a reasonable and feasible first step for implementation standardizing care without
adversely affecting patient safety or outcomes [45, 46]. Moreover, annual PPS could be a useful
tool to measure the impact of these interventions on antibiotic prescribing practices [18]. Thus,
implementation of clinical pathways in Italian paediatric hospitals associated with annual PPSs
could be a good start to reduce the abuse and misuse of antibiotics.
Our study has some limitations. First, data about microbiological isolates and antibiotic sus-
ceptibility tests, length of therapies and prophylaxis and previous antibiotic courses could have
been useful to better define the appropriateness of antimicrobial prescriptions. Moreover, the
characteristics of involved institutions may have affected at least in part the reliability of some
results. Most institutions are in fact tertiary care hospitals that usually manage more compli-
cated and severe cases, which might significantly impact antibiotic prescriptions. In addition,
the heterogeneity among institutions, in terms of presence/absence of onco-hematology
departments or intensive care units, may strongly affect antimicrobial prescription patterns.
Finally, the survey was conducted in 2012 and since then a greater awareness of antibiotic stew-
ardship programs has spread among Italian hospitals [47–49].
Conclusions
Our study took a picture of the Italian situation in terms of antibiotic prescriptions in hospital-
ized neonates and children and identified many feasible targets that require a prompt interven-
tion to reduce the abuse and misuse of antibiotics. Antibiotic stewardship programs should
immediately introduce measures to control prescription patterns in particular for prophylaxis,
both in neonatal and paediatric populations, and to limit the over-use of third generation ceph-
alosporins, that seems to persist over-time. Surveillance and educational programs are also
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needed to restrict the use of carbapenems to more severe conditions. The implementation of
disease-specific clinical pathways associated with annual PPSs could be a good way to monitor
and ameliorate antibiotic prescription patterns in neonatal and paediatric inpatients over time,
in order to reduce as much as possible the worrisome emergence of MDR bacteria in this vul-
nerable population.
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